AVITA Medical (NASDAQ:RCEL) Given “Buy” Rating at D. Boral Capital
D. Boral Capital restated their buy rating on shares of AVITA Medical (NASDAQ:RCEL – Free Report) in a research note released on Thursday,Benzinga reports. The firm currently has a $22.00 target price on the stock. RCEL has been the topic of several other reports. Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price […]
D. Boral Capital restated their buy rating on shares of AVITA Medical (NASDAQ:RCEL – Free Report) in a research note released on Thursday,Benzinga reports. The firm currently has a $22.00 target price on the stock. RCEL has been the topic of several other reports. Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price […]
